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BACKGROUND: Socioeconomic status (SES) and social support influences cancer survival. If SES and social support affects cancer
treatment has not been thoroughly explored.
METHODS: A cohort consisting of all patients who were initially diagnosed with or who developed metastatic colorectal cancer
(mCRC, n¼ 781) in three Scandinavian university hospitals from October 2003 to August 2006 was set up. Clinical and
socioeconomic data were registered prospectively.
RESULTS: Patients living alone more often had synchronous metastases at presentation and were less often treated with combination
chemotherapy than those cohabitating (HR 0.19, 95% CI 0.04–0.85, P¼ 0.03). Surgical removal of metastases was less common in
patients living alone (HR 0.29, 95% CI 0.10–0.86, P¼ 0.02) but more common among university-educated patients (HR 2.22, 95% CI
1.10–4.49, P¼ 0.02). Smoking, being married and having children did not influence treatment or survival. Median survival was 7.7
months in patients living alone and 11.7 months in patients living with someone (Po0.001). Living alone remained a prognostic factor
for survival after correction for age and comorbidity.
CONCLUSION: Patients living alone received less combination chemotherapy and less secondary surgery. Living alone is a strong
independent risk factor for poor survival in mCRC.
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A large number of studies have shown that overall and cancer-
specific survival is better in individuals with high socioeconomic
status (SES) (Bentley et al, 2008; Byers et al, 2008; Halmin et al, 2008;
Harris et al, 2009; Aarts et al, 2010; Cavalli-Bjorkman et al, 2011).
Socioeconomic status is usually defined by factors such as maximum
attained level of education, income (own/family’s/neighbourhood’s),
and overall standard of living (Blais et al, 2006). Although strictly
not contributing to SES, social network has been studied in this
context and patients with few friends and family members have
been shown to have shorter cancer survival than those with a large
social sphere (Goodwin et al, 1987; Reynolds et al, 1994; Datta
et al, 2009; Chou et al, 2010). In controlled studies on cancer
survival, the relative risk for mortality of married respondents
was 12% lower than that of unmarried persons (Pinquart and
Duberstein, 2010).
Reasons for poorer outcome in socially deprived patients might
be more advanced disease at presentation, comorbidity and
treatment-related morbidity (Frederiksen et al, 2009; Hines et al,
2009; Fusco et al, 2010). Difficulty in accessing health care may
also be a factor (Lejeune et al, 2010; Sankaranarayanan et al, 2010;
Baade et al, 2011). Proposed explanations for the importance of
social support range from psychosocial ones (more meaningful to
prolong survival when surrounded by loved ones) to the benefit
reaped from practical help during cancer treatment. There is also a
possibility that patients with low SES and/or poorer social support
are offered different treatment for cancer than more privileged
patients (Dobie et al, 2006; Villingshoj et al, 2006; McBride et al,
2010; van Steenbergen et al, 2010). If patients’ SES or social
situation determines which treatment they are offered the reasons
for this need to be more fully understood. In the present study, the
setting is Scandinavia, where healthcare is tax financed and freely
available to all citizens regardless of social standing. Cancer
treatment is exclusively administered at government-funded
hospitals and not at private clinics. Treatment guidelines are
regularly updated to promote fair and equal treatment for
patients of different geographic regions. If treatment were to
vary by social standing in Scandinavia, it could mean that
doctors take the patient’s SES and/or social circumstances into
account when designing cancer treatment (Lemmens et al, 2005;
Tilney et al, 2009).
The aim of the present study was to explore treatment and
survival in a Scandinavian, population-based, cohort of metastatic
colorectal cancer (mCRC) patients stratified for indicators of SES
and social support.
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MATERIALS AND METHODS
On 1st October 2003, prospective registration of patients with
mCRC referred to oncology units of three university hospitals was
initiated. The aim was to use hospitals which received all referrals
to an oncology department of that region, that is, hospitals in
regions where there was only one oncology department providing
radiation therapy and medical treatment for adult cancer patients.
Uppsala University Hospital in Sweden serves a region ofB280 000
inhabitants, Odense University Hospital in Denmark serves
475 000 and Haukeland University Hospital in Norway 450 000
people. All patients in these three areas who need oncologic
treatment will be referred to the only university hospital in that
region. A cohort consisting of all patients who were initially diagnosed
with or who developed metastases from CRC and who were referred to
these oncology departments until 1st August 2006 was created.
The cohort consisted of 781 patients, 296 from Norway, 323
from Denmark and 162 from Sweden. All patients had stage IV
histologically confirmed adenocarcinoma of the colon or rectum.
They completed questionnaires regarding medical history, family
structure, maximum level of attained education and smoking
habits at the first consultation. We prospectively recorded clinical
characteristics, comorbid conditions, routine blood tests, treat-
ment offered and whether the patient was included in a clinical
trial or not. Missing data has been retrospectively retrieved from
the patients’ files. The cohort was originally set up with the
primary intent to study trial inclusion, and the results from this
project have been previously published (Sorbye et al, 2009).
Socioeconomic status and social support
Disease-related factors were tested against five variables: marriage/
cohabitation with a partner, having children, living alone, smoking
and maximum level of education. The first four variables were
answered by either ‘yes’ or ‘no’, whereas educational level was split
in two groups: maximum level 12 years of school (non-university),
and university or the equivalent. In Scandinavia cohabitation,
without being married, is common and for the purpose of this
study cohabitation with a partner is considered equal to marriage.
Married patients were further divided by sex, as it had been
reported that men and women benefit differently from the
educational level of their spouse (Jaffe et al, 2006).
Other variables
Co-morbidity was sub-classified into diabetes, cardiovascular,
pulmonary and psychiatric, but for the purpose of these analyses
only division into comorbidity/ no comorbidity was used. In a
Dutch colon cancer study, further subdivision of comorbidity
according to a modified Charlson classification did not improve
the interpretation of comorbidity data (Lemmens et al, 2005). The
patients were divided into two groups: those with metastatic
disease at presentation (synchronous metastases) and those who
had developed metastases after initially having had localised
disease (metachronous metastases). If metastases were found
within 90 days of the initial diagnosis, the patient was considered
to have synchronous metastases. At the patients’ first consultation,
performance status (PS) was scored using the WHO classification
and patients were divided into four groups: PS 0, 1, 2 and 3–4. The
latter were grouped together as they constitute patients generally
considered ineligible for palliative chemotherapy. Combination
chemotherapy, that is, an irinotecan or oxaliplatin combination
with 5-fluorouracil (5-FU), was administered to 350 patients
(Table 1). Bevacizumab and cetuximab were grouped together
under ‘antibody treatment’. Some cohort patients (n¼ 55) were
included in the randomised Nordic VII trial, where 2 out of 3 of
patients were given cetuximab as first-line treatment. As trial
inclusion was a factor to be analysed, we chose to limit the
antibody group to patients treated outside of a clinical trial.
Patients over the age of 75 were excluded from analyses on
antibody treatment and secondary surgery as novel treatments
were rarely used for elderly patients during this time frame. Data
on age and comorbidity were used to adjust results.
Statistical methods
As the numbers of events in some categories were few, statistical
analysis had to be adjusted. Combination chemotherapy, adminis-
tered to 350 patients, was compared with the 100 patients receiving
only 5-FU. The smallest group in this category limited the
statistical model, which led to omission of analysis on possible
Table 1 Patient characteristics of all registered patients (n¼ 781)
n % Missing, n
Median age 71 (22–95) 0
Gender 0
Male 414 53
Female 367 47
Type of metastasising 0
Synchronous metastases 433 55
Metachronous metastases 348 45
Colon primary 521 67 0
Surgery of primary tumour 570 73 0
Performance status, WHO 17
0 253 32
1 217 28
2 156 20
3þ 4 138 18
Comorbid conditions 8
With comorbidity 443 57
Without comorbidity 330 42
Marital status 11
Married/cohabitating 517 66
Single 253 32
Parenting 22
Patients with children 661 85
Patients without children 98 13
Living arrangements 13
Living alone 245 31
Living with someone 523 67
Smoking status 75
Smokers 178 23
Non-smokers 528 68
Educational level 114
Non-university 574 73
University 93 12
Oncological treatment 1
Active treatment 465 60
Combination chemotherapy 350 45
Best supportive care 315 40
Antibody treatment 0
Treated with cetuximab 108 14
Not treated with cetuximab 673 86
Treated with bevacizumab 49 6
Not treated with bevacizumab 732 94
Secondary surgery 7
Surgical removal of metastases 49 6
No secondary surgery 725 93
Clinical trial participation 1
Trial inclusion 169 22
No trial inclusion 611 78
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effects on marital status. The smallest group treated (49 patients)
was the group who had secondary surgery for metastases and the
number of factors, which we could test with accuracy, were
calculated to be three. For multivariate analyses in Table 2, the
analyses for secondary surgery had to be limited to living alone,
having children and educational level. Logistic regression was used
for dichotomous and ordinal logistic regression for ordinal
outcome variables, with multiple imputations to reduce loss of
data due to missing values in the covariates. Two group
comparisons were performed using exact chi-square tests for
dichotomous or nominal variables, exact Mann–Whitney tests for
ordinal variables, and Student t-tests for continuous variables.
Overall survival analyses for all patients were performed for the
time interval from the date of non-resectable metastatic disease to
the date of death or censored if the patient was alive on 15 August
2008, using the Kaplan–Meier method with log-rank tests for
univariate and Cox regression for multivariate analyses. Overall,
rather than cancer-specific, survival was opted for since it was of
interest to study influence of comorbidity on treatment and
survival. A separate Cox regression analysis was done to deduce
possible confounding effects of high age and comorbidity on
survival in patients living alone. The proportional hazard
assumptions were checked as recommended by Therneau and
Grambsch, 2000.
All analyses were performed with the statistical programme:
R version 2.10.0 (The R Foundation for Statistical Computing,
Vienna, Austria), using the R package rms for regression analyses.
The function aregImpute in the R package Hmisc functions was
used for multiple imputations (200 imputed data sets).
All statistical tests were two tailed, using the 5% significance
level.
RESULTS
Patient characteristics
Baseline patient characteristics of all registered patients in the
cohort are shown in Table 1. As the cohort was population-based
and patients were consecutively included, a large percentage of
patients were older and had poor performance status. More than
half of the patients had significant comorbid conditions, as judged
by the attending physicians.
Disease characteristics and treatment
Table 2 shows results of multivariate analyses with adjustment for
age and comorbidity. Patients who lived alone more often
presented with metastatic disease than those who lived with
someone (OR 2.17, 95% CI 1.32–3.55) and were less often treated
with combination chemotherapy (OR 0.19, 95% CI 0.04–0.85) and
secondary surgery of metastases (OR 0.29, 95% CI 0.10–0.86).
Patients with university education more often had surgery of
metastases than patients with non-university education (OR 2.22,
95% CI 1.10–4.49). Smokers had poorer PS than non-smokers at
baseline (OR 1.65, 95% CI 1.19–2.29). No differences in disease
stage, PS and treatment given were seen with respect to marital
status and having children. With the exception of surgery for liver
or lung metastases, educational attainment did not influence
treatment.
Survival
Median survival times stratified by educational level, comorbidity
and indicators of social support are shown in Table 3. Differences
in overall survival were seen between patients living alone and
those living with someone (7.7 vs 11.7 months, Po0.001). Similar
survival differences were seen between patients with and without
comorbidity (8.0 vs 12.5 months, P¼ 0.01). No significant
differences in survival were seen with regard to smoking, marital
status, educational level and having children. Cox regression
analysis showed that living alone (HR 1.19, 95% CI 1.01–1.41,
P¼ 0.03) and higher age (HR 1.03, 95% CI 1.02–1.03, Po0.001)
were independent prognostic factors for survival, whereas
comorbidity was not. When checking proportional hazard
assumptions, the global test showed significant deviations
(Po0.001). No deviations were indicated for living alone
(P¼ 0.208), but for both adjustments variables age (Po0.001)
Table 2 Multivariate analyses (ordinal regression) of disease characteristics and treatment by education and family structure
Dependent variables
Patients
living alone
Patients
with children
Patients with
higher education Married women Married men Smokers
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
Independent variables
Synchronous
metastases
2.17 1.32–3.55 0.002 0.88 0.55–1.40 0.59 1.04 0.66–1.63 0.87 1.15 0.68–1.93 NSa 1.57 0.93–2.66 NSa 1.11 0.78–1.59 0.55
Poor
performance
status
0.78 0.48–1.21 0.27 0.83 0.54–1.27 0.36 1.03 0.67–1.56 0.9 0.74 0.46–1.20 NSa 0.74 0.46–1.20 NSa 1.65 1.19–2.29 0.003
Active
anti-cancer
treatment
0.98 0.46–2.10 0.96 0.58 0.29–1.16 0.12 1.31 0.61–2.83 0.49 1.85 0.82–4.16 NSa 1.57 0.70–3.52 NSa 0.84 0.49–1.44 0.52
Trial
participation
1.22 0.50–2.96 0.66 1.42 0.70–2.91 0.32 1.13 0.62–2.07 0.68 1.41 0.57–3.50 NSa 1.11 0.44–2.81 NSa 0.90 0.53–1.53 0.7
Cetuximab/
bevacizumab
treatment
0.98 0.38–2.51 0.96 1.05 0.47–2.38 0.9 1.31 0.71–2.41 0.39 2.1 0.78–5.65 NSa 2.17 0.79–5.95 NSa 0.92 0.52–1.63 0.78
Combination
chemotherapy
0.19 0.04–0.85 0.03 1.29 0.40–4.15 0.67 1.92 0.62–5.93 0.26 b b b b b b 1.66 0.72–3.84 0.24
Secondary
surgery of
metastases
0.29 0.10–0.86 0.02 0.91 0.33–2.50 0.85 2.22 1.10–4.49 0.02 b b b b b b b b b
Abbreviations: CI¼ confidence interval; NS¼ not significant; OR¼ odds ratio. Adjustment for age and comorbidity done in all analyses. aAnalysis not done for married men and
women separately as overall value was not statistically significant. bAnalysis not done due to small number of patients in analysis.
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and comorbidity (P¼ 0.012). Plots of Schoenfeld residuals
indicated that age may be less influential as the disease progresses
while comorbidity may be a risk factor around the time of
diagnosis of mCRC.
DISCUSSION
In this population-based mCRC cohort, patients who lived alone
had more advanced disease at presentation were less likely to
receive potent combination chemotherapy regimens and had
poorer survival than those who lived with someone. As data has
been adjusted for age and comorbidity, it is not possible to explain
the above by hypothesising that patients who live alone are old and
frail with poor PS. Reports that focus on treatment of cancer
patients who live alone are scarce. In an American study on
survival of head–neck cancer patients, men without a partner were
found to have considerably shorter survival even after controlling
for disease variables (Konski et al, 2006). Other studies have found
that patients with Non-Hodgkin lymphoma (Frederiksen et al,
2011) and lung cancer (Dalton et al, 2011) present with later stages
of their respective diseases if they live alone than if they live with
someone. To our knowledge, it has not been shown previously that
lowered treatment intensity might be a contributing factor to the
shorter survival of patients who live alone. This is of concern
because of the large number of people who live by themselves – a
phenomenon which is becoming increasingly common, especially
in urban areas.
It is reasonable to speculate that the absence of a partner can
delay diagnosis as the patient lacks the social support needed to
actively pursue medical help. It is also possible that these patients
may be, consciously or subconsciously, judged by physicians as
being without the support to qualify them for more intensive
oncologic treatment. Knowing that patients have strong networks
enables clinicians to risk treatment with potentially serious
side-effects. Further, the choice between undergoing potentially
life-prolonging treatment while sometimes enduring considerable
toxicity, or declining treatment, has to be made by the patient. We
cannot rule out the possibility that the will to have such treatment
is stronger in patients who live with someone than it is in those
who do not.
Colorectal cancer treatment has developed immensely in the
last decade. In the 1980s it was not certain that mCRC patients had
any benefit from chemotherapy at all. A few studies subsequently
showed that 5-FU alone gave slightly prolonged survival, and in the
1990s addition of oxaliplatin and irinotecan improved survival
even more (Glimelius and Cavalli-Bjorkman, 2012). As it is clear
that combining 5-FU with oxaliplatin or irinotecan prolongs survival,
we must see a connection between patients living alone receiving less
combination chemotherapy and having shorter survival.
During the time frame that the cohort in this study was set up,
targeted drugs in the form of antibodies were tested, mainly within
the confines of clinical trials. The three Scandinavian countries
have very similar treatment guidelines for mCRC patients. If the
patient’s PS is good enough patients in all three countries will be
recommended to receive sequential treatment of 5-FU, oxaliplatin
and irinotecan, in different combinations and different orders,
provided toxicity is acceptable and the disease responds favour-
ably. In some instances, antibody will be added. The only
difference between the countries is that Norway does not generally
recommend palliative chemotherapy for patients over the age
of 75. In our cohort, patients over this age were excluded from
analysis and results were thus not affected by this.
Marital status has previously been studied and as a marker for
social support some groups have found advantages for married
patients with regard to cancer survival (Patel et al, 2010). We were
not able to verify this in our material. However, being married is
not always the same as living with someone. In large register
studies, married patients may be perceived as having good family
support. In our cohort, some patients were married but lived apart
as the spouse was in a nursing home. We also included patients
living with their adult children into the group of cohabitating
patients as we felt this reflected a dimension of social support. An
individual evaluation of the patients’ living arrangements, as was
possible in this prospectively collected cohort, is likely to be a
more accurate way to study the effect of social support than to
simply look at marital status.
Having children can mean different things to different people –
when relationships with offspring are close it means increased
social support, but not all people remain in contact with adult
children. Because of this discrepancy, having children, as an SES
parameter, is probably not very reliable in indicating good network
and support. Having a live-in-partner is more likely to be
indicative of solid family structure in this sense.
Maximum attained educational level has traditionally been used
as a strong indicator of SES. In the Scandinavian countries it is
more likely to reflect SES than income or area of residence and has
been used in a number of studies on cancer and SES (Eaker et al,
2009; Berglund et al, 2010). When using social databases to extract
information on occupation, employment status, income and
socioeconomic index, all factors have followed the trend set by
educational level (Eaker et al, 2009; Cavalli-Bjorkman et al, 2011).
Register studies in Scandinavia and elsewhere have shown that
there are differences in diagnostic activity, treatment and survival
by educational level (Halmin et al, 2008). One major drawback in a
number of these studies has been the lack of information on
comorbidity (Halmin et al, 2008; Cavalli-Bjorkman et al, 2011).
There is strong evidence that the prevalence of comorbid
conditions is higher in groups with lower SES (Louwman et al,
2010). Many studies on SES and cancer have been inconclusive as
data could not be adjusted for comorbidity. Interestingly, in the
smaller cohort of patients in the present study we could not verify
differences by educational level with the exception of secondary
surgery for distant metastases. It is possible that this is because we
have the advantage of detailed information on patients’ comor-
bidity and we have been able to adjust for this. We have, on 773
patients in the cohort (99%), scored and sub-classified
Table 3 Median overall survival in different patient groups
Months (95% CI) P-value (log-rank)
Patients living alone
Yes 7.7 (6.3–9.8)
No 11.7 (10.3–13.1) o0.001
Patients with children
Yes 10.5 (9–11.6)
No 9.3 (7.1–12.4) 0.451
Patients with higher education
Yes 11.5 (9.1–15.2)
No 11.2 (9.5–12.4) 0.574
Patients with comorbidity
Yes 8.0 (6.7–10)
No 12.5 (11.3–14.8) 0.009
Marital status
Married women 12.5 (10.4–15.4)
Married men 11.2 (8.6–13.2) 0.216
Smokers
Yes 8.3 (5.9–12.8)
No 10.9 (9.3–11.9) 0.349
Abbreviation: CI¼ confidence interval.
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comorbidity from an oncologists’ point of view. As some
comorbidity contraindicates chemotherapy while other diseases
do not, this is an asset in the present study.
Compared with other countries’ treatment frequencies, some of
the percentages in this study can seem low. Secondary curative
surgery, for instance, is usually reported to be performed in
10–15% of the patients, whereas in our study the number was 6%.
As this cohort is population based and includes all consecutive
patients with mCRC, it well represents the general population of
stage IV CRC patients. In this cohort treatment and outcome are
poorer than in clinical trials, where patients often are highly
selected. Almost 20% of patients presented with PS 3 or worse,
automatically disqualifying them from chemotherapy, and many
patients were elderly. Overall survival is also much shorter than in
other patient series. Again this reflects the population-based
nature of the patient material; overall survival in patients treated
with combination therapy or in a clinical trial was similar to all
other series, or close to 2 years (Sorbye et al, 2009). Bevacizumab
treatment was quite rare in this cohort. This is best explained by
the clinical trials that were ongoing during the years 2003–2006.
The trials, in all three countries, recruited more patients to
treatment with cetuximab than bevacizumab. During this time
frame patients were not selected for treatment with cetuximab
based on their K-ras-status.
In Scandinavia regional oncologic centres work towards equal
treatment for all patients regardless of background and place of
habitation. National guidelines approved by the National Health
authorities for both adjuvant and palliative treatment are produced
in conjunction with these centres. This may in itself lessen the risk
of unequal treatment, and many clinicians feel that inequality in
the public health care sector is not a prevailing problem. We did
not find significant differences between patients of different
educational level and social situation with the exception of patients
living alone. This is an interesting finding which deserves attention
as it may be a factor which subconsciously influences the decisions
made by oncologists for cancer patients. If patients can be offered
better support, it may be possible to increase treatment intensity
and prolong survival in this group.
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